Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity

Toxicology

Volumn 329, Issue , 2015, Pages 40-48

  Gee, Rowena H ^a   Spinks, Jenny N ^a   Malia, Jason M ^a   Johnston, Jonathan D ^a   Plant, Nick J ^a   Plant, Kathryn E ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Cholesterol; HMG COA; Prenylation; Statin toxicity

Indexed keywords

ATORVASTATIN; CERIVASTATIN; DIMETHYLALLYLTRANSFERASE; FLUINDOSTATIN; GERANYLGERANYL TRANSFERASE 1; GERANYLGERANYL TRANSFERASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE; RAP 1 A PROTEIN; RAP1 PROTEIN; ROSUVASTATIN; SIMVASTATIN; TRANSFERASE; UNCLASSIFIED DRUG; GERANYLGERANYLTRANSFERASE TYPE-I; MEMBRANE PROTEIN; RAP1A PROTEIN, HUMAN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LIVER TOXICITY; MYOPATHY; PRIORITY JOURNAL; PROTEIN PRENYLATION; RHABDOMYOSARCOMA CELL LINE; TARGET CELL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; HYPERCHOLESTEROLEMIA; LIVER; METABOLISM; MUSCLE DISEASE; PATHOLOGY; PRENYLATION; PROTEIN PROCESSING; SKELETAL MUSCLE; TUMOR CELL LINE;

ALKYL AND ARYL TRANSFERASES; CELL LINE, TUMOR; DIMETHYLALLYLTRANSTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER; MEMBRANE PROTEINS; MEVALONIC ACID; MUSCLE, SKELETAL; MUSCULAR DISEASES; PRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RAP1 GTP-BINDING PROTEINS; SIMVASTATIN;

EID: 84921531823     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2015.01.005     Document Type: Article

References (48)

1. Al-Salman F., Plant N. Non-coplanar polychlorinated biphenyls (PCBs) are direct agonists for the human pregnane-X receptor and constitutive androstane receptor, and activate target gene expression in a tissue-specific manner. Toxicol. Appl. Pharmacol. 2012, 263:7-13.
2. Arora R., Liebo M., Maldonado F. Statin-induced myopathy: the two faces of Janus. J. Cardiovasc. Pharmacol. Ther. 2006, 11:105-112.
3. Bjorkhem-Bergman L., Lindh J.D., Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects?. Br. J. Clin. Pharmacol. 2011, 72:164-165.
4. Blanco-Colio L.M., Villa A., Ortego M., Hernandez-Presa M.A., Pascual A., Plaza J.J., Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002, 161:17-26.
5. Cui Y.H., Konig J., Nies A.T., Pfannschmidt M., Hergt M., Franke W.W., Alt W., Moll R., Keppler D. Detection of the human organic anion transporters SLUM (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. 2003, 83:527-538.
6. Elphick L.M., Pawolleck N., Guschina I.A., Chaieb L., Eikel D., Nau H., Harwood J.L., Plant N.J., Williams R.S.B. Conserved valproic-acid-induced lipid droplet formation in dictyostelium and human hepatocytes identifies structurally active compounds. Dis. Models Mechan. 2012, 5:231-240.
7. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
8. Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La Grenade L., Gurwitz J.H., Chan K.A., Goodman M.J., Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. J. Am. Med. Assoc. 2004, 292:2585-2590.
9. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., Diaz C., Hernandez G., Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res. 1998, 83:490-500.
10. Hohl R.J., Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J. Biol. Chem. 1995, 270:17508-17512.
11. Howe K., Sanat F., Thumser A.E., Coleman T., Plant N. The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes. Xenobiotica 2011, 41:519-529.
12. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292:1160-1164.
13. Itagaki M., Takaguri A., Kano S., Kaneta S., Ichihara K., Satoh K. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J. Pharmacol. Sci. 2009, 109:94-101.
14. Johnson T.E., Zhang X.H., Bleicher K.B., Dysart G., Loughlin A.F., Schaefer W.H., Umbenhauer D.R. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol. Appl. Pharmacol. 2004, 200:237-250.
15. Joshi H.N., Fakes M.G., Serajuddin A.M. Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity. Pharm. Pharmacol. Commun. 1999, 5:269-271.
16. Knudsen E.S., Pazzagli C., Born T.L., Bertolaet B.L., Knudsen K.E., Arden K.C., Henry R.R., Feramisco J.R. Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD1. Cancer Res. 1998, 58:2042-2049.
17. Kolodkin A., Sahin N., Phillips A., Hood S.R., Bruggeman F.J., Westerhoff H.V., Plant N. Optimization of stress response through the nuclear receptor-mediated cortisol signalling network. Nat. Commun. 2013, 4:1972.
18. Kolodkin A.N., Bruggeman F.J., Plant N., Mone M.J., Bakker B.M., Campbell M.J., van Leeuwen J., Carlberg C., Snoep J.L., Westerhoff H.V. Design principles of nuclear receptor signaling: how complex networking improves signal transduction. Mol. Syst. Biol. 2010, 6:446.
19. Lerner E.C., Qian Y.M., Blaskovich M.A., Fossum R.D., Vogt A., Sun J.Z., Cox A.D., Der C.J., Hamilton A.D., Sebti S.M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic RAS signaling by inducing cytoplasmic accumulation of inactive RAS-RAF complexes. J. Biol. Chem. 1995, 270:26802-26806.
20. Lin J., Schyschka L., Muhl-Benninghaus R., Neumann J., Hao L.P., Nussler N., Dooley S., Liu L.G., Stockle U., Nussler A.K., Ehnert S. Comparative analysis of phases I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism. Arch. Toxicol. 2012, 86:87-95.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
22. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J. Am. Coll. Cardiol. 2007, 49:2231-2237.
23. Matzno S., Yasuda S., Juman S., Yamamoto Y., Nagareya-Ishida N., Tazuya-Murayama K., Nakabayashi T., Matsuyama K. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J. Pharm. Pharmacol. 2005, 57:1475-1484.
24. McAllister M.D., Melnyk J., Finklest J.Z., Adams E.C., Gardner M.B. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 1969, 24:520.
25. Morck C., Olsen L., Kurth C., Persson A., Storm N.J., Svensson E., Jansson J.-O., Hellqvist M., Enejder A., Faergeman N.J., Pilon M. Statins inhibit protein lipidation and induce the unfolded protein response in the non-sterol producing nematode Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18285-18290.
26. 12 myotubes and HepG2 cells: and consequences for statin-induced myopathy. Biochem. Pharmacol. 2010, 79:1200-1209.
27. Mullen P.J., Zahno A., Lindinger P., Maseneni S., Felser A., Krahenbuhl S., Brecht K. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim. Biophys. Acta: Mol. Cell Res. 2011, 1813:2079-2087.
28. Nakabayashi H., Taketa K., Miyano K., Yamane T., Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982, 42:3858-3863.
29. Nishimoto T., Ishikawa E., Anayama H., Hamajyo H., Nagai H., Hirakata M., Tozawa R. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol. Appl. Pharmacol. 2007, 223:39-45.
30. Nishimoto T., Tozawa R., Amano Y., Wada T., Imura Y., Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem. Pharmacol. 2003, 66:2133-2139.
31. Obaidat A., Roth M., Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Ann. Rev. Pharmacol. Toxicol. 2012, 52:135-151.
32. Plant K.E., Anderson E., Simecek N., Brown R., Forster S., Spinks J., Toms N., Gibson G.G., Lyon J., Plant N. The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol. Appl. Pharmacol. 2009, 235:124-134.
33. Plant N. Strategies for using in vitro screens in drug metabolism. Drug Discov. Today 2004, 9:328-336.
34. Plant N. The human cytochrome P450 3A sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim. Biophys. Acta - Gen. Subjects 2007, 1770:478-488.
35. Qian Y.M., Vogt A., Vasudevan A., Sebti S.M., Hamilton A.D. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorg. Med. Chem. 1998, 6:293-299.
36. Rauthan M., Ranji P., Pradenas N.A., Pitot C., Pilon M. The mitochondrial unfolded protein response activator ATFS-1 protects cells from inhibition of the mevalonate pathway. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5981-5986.
37. Rodrigues A.C., Curi R., Genvigir F.D.V., Hirata M.H., Hirata R.D.C. The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells. Acta Pharmacol. Sin. 2009, 30:956-964.
38. Rossi S., Stoppani E., Puri P.L., Fanzani A. Differentiation of human rhabdomyosarcoma RD cells is regulated by reciprocal, functional interactions between myostatin, p38 and extracellular regulated kinase signalling pathways. Eur. J. Cancer 2010, 47:1095-1105.
39. Sakamoto K., Honda T., Yokoya S., Waguri S., Kimura J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. Faseb J. 2007, 21:4087-4094.
40. Sakamoto K., Wada I., Kimura J. Inhibition of Rab1 GTPase and endoplasmic reticulum-to-golgi trafficking underlies statin's toxicity in rat skeletal myofibers. J. Pharmacol. Exp. Ther. 2011, 338:62-69.
41. Satoh K., Ichihara K., Landon E.J., Inagami T., Tang H. 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells - involvement of geranylgeranylation of small G protein Rap1. J. Biol. Chem. 2001, 276:15761-15767.
42. Serajuddin A.T.M., Ranadive S.A., Mahoney E.M. Relative lipophilicities, solubilities, and structure pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme-A (Hmg-Coa) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 1991, 80:830-834.
43. Siddals K.W., Marshman E., Westwood M., Gibson J.M. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J. Biol. Chem. 2004, 279:38353-38359.
44. Spindler S.R., Li R., Dhahbi J.M., Yamakawa A., Mote P., Bodmer R., Ocorr K., Williams R.T., Wang Y., Ablao K.P. Statin treatment increases lifespan and improves cardiac health in drosophila by decreasing specific protein prenylation. Plos One 2012, 7:e39581.
45. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1712-1719.
46. Wasko B.M., Dudakovic A., Hohl R.J. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J. Pharmacol. Exp. Ther. 2011, 337:540-546.
47. Westwood F.R., Scott R.C., Marsden A.M., Bigley A., Randall K. Rosuvastatin: characterization of induced myopathy in the Rat. Toxicol. Pathol. 2008, 36:345-352.
48. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. 1996, 65:241-269.